We currently lack serological assays suitable to specifically detect SARS-CoV-2 antibodies, of critical importance to determine seroprevalence in a given population, define previous exposure and identify highly reactive human donors for the generation of convalescent serum as therapeutic.
Importantly, the assays described here do not require handling of infectious virus, can be adjusted to detect different antibody types and are amendable to scaling. Deployment will also support screening of health care workers to identify those who are already immune and can be deployed to care for infected patients minimizing the risk of viral spread to colleagues and other patients.
A serological assay to detect SARS-CoV-2 seroconversion in humans. doi: https://doi.org/10.1101/2020.03.17.20037713. This article is a preprint and has not been peer-reviewed.
This information is not intended as medical advice or clinician guidance. This content contains edited excerpts to bring attention to the work of the researchers and study authors. Please support their efforts and click through for the full context.
